Home » Priority Review Voucher Fees Cut for Fiscal Year 2020
Priority Review Voucher Fees Cut for Fiscal Year 2020
Effective Oct. 1, drugmakers will have to pay $2,167,116 million to redeem a priority review voucher for a newly approved drug or biologic for treatment of a rare pediatric disease, a tropical disease or for a medical countermeasure.
The cost of redeeming vouchers has dropped dramatically from over $5 million in 2012. The new fee represents an11.8 percent drop from the fiscal 2019 fee of $2.45 million.
The Congress created the PRV program in 2007, under which the FDA aims to review applications within six months.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May